← Leaderboards
Richard Scranton
Lyndra Therapeutics, Inc.
$12,106,230
Attributed
$24,212,460
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.5M · FY2019–21$20M$15M$10M$5M$0
'19
'20
'21
Funding mix
By agency
NIH$24,212,460 · 3
By mechanism
UG3$12,512,667 · 2
UH3$11,699,793 · 1
Top collaborators
- Patrick Boen2 shared
- Stephen Zale1 shared
Most similar at Lyndra Therapeutics, Inc.
Same institution · by research overlap
- Andrew Martin Bellinger$10,090,927
- Patrick Boen$8,679,033
- Stephen Zale$5,700,018
Others in their field
Other Emerging Leaders on “Fda Approved”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Xinhua Li · Nano Terra, Inc.$32,520,955
- Klaus Romero · Critical Path Institute$31,739,260
- James Dale Berry · Brigham And Women'S Hospital$26,348,733
- Andrew S Huhn · Johns Hopkins University$17,756,243
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Fda ApprovedGastric RetentionEvaluationDirectly Observed TherapyDrug Delivery SystemsFormulationAmendmentDosage FormsBaseAnimal ModelAlzheimer&AposDoseAnimalsFirst-In-HumanClinical CandidateClinical DataClinical DevelopmentClinical MaterialClinical ResearchClinical TrialsCompliance BehaviorBiological AvailabilityCyclic GmpGovernment
Grant awards (3)
A once-weekly oral methadone for maintenance therapy for opioid use disorder$11,699,793
UH3 · FY2021 · DA · contact PI
A once-weekly oral methadone for maintenance therapy for opioid use disorder$6,854,394
UG3 · FY2019 · DA
An ultra-long-acting oral treatment for opioid use disorder$5,658,273
UG3 · FY2019 · DA